All News #Library
Rare Diseases
Exidavnemab phase 2a study expanded to include MSA patients
08 May 2025 //
PR NEWSWIRE
Eisai presents Leqembi® sales simulation at annual conference
25 Mar 2025 //
PR NEWSWIRE
BioArctic receives Orphan Drug Designation for exidavnemab the US
17 Mar 2025 //
PR NEWSWIRE

Market Place
Sourcing Support